Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System
Ana Belén Herrera-Campos 1, Esteban Zamudio-Martinez 1 2, Daniel Delgado-Bellido 1 2, Mónica Fernández-Cortés 1 2, Luis M Montuenga 2 3 4, F Javier Oliver 1 2, Angel Garcia-Diaz 1 2
Hyperoxia is used in order to counteract hypoxia effects in the TME (tumor microenvironment), which are described to boost the malignant tumor phenotype and poor prognosis.
The reduction of tumor hypoxic state through the formation of a non-aberrant vasculature or an increase in the toxicity of the therapeutic agent improves the efficacy of therapies such as chemotherapy. Radiotherapy efficacy has also improved, where apoptotic mechanisms seem to be implicated.
Moreover, hyperoxia increases the antitumor immunity through diverse pathways, leading to an immunopermissive TME. Although hyperoxia is an approved treatment for preventing and treating hypoxemia, it has harmful side-effects.
Prolonged exposure to high oxygen levels may cause acute lung injury, characterized by an exacerbated immune response, and the destruction of the alveolar-capillary barrier. Furthermore, under this situation, the high concentration of ROS may cause toxicity that will lead not only to cell death but also to an increase in chemoattractant and proinflammatory cytokine secretion. This would end in a lung leukocyte recruitment and, therefore, lung damage. Moreover, unregulated inflammation causes different consequences promoting tumor development and metastasis. This process is known as protumor inflammation, where different cell types and molecules are implicated; for instance, IL-1β has been described as a key cytokine.
Although current results show benefits over cancer therapies using hyperoxia, further studies need to be conducted, not only to improve tumor regression, but also to prevent its collateral damage.
Keywords: hyperoxia; hypoxia; immunotherapy; inflammation; tumor microenvironment.
CITA DEL ARTÍCULO Cancers (Basel). 2022 May 31;14(11):2740. doi: 10.3390/cancers14112740.